References

Pre- and post-treatment blood-based genomic landscape of patients with

10.1002/1878-0261.13214 · ExternalCitation · doi-reference

Current status of precision oncology in adult glioblastoma

10.1002/1878-0261.13678 · ExternalCitation · doi-reference

Novel ATP‐competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells

10.1002/cam4.1179 · ExternalCitation · doi-reference

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma

10.1002/cam4.2505 · ExternalCitation · doi-reference

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low‐grade glioma

10.1002/cncr.26541 · ExternalCitation · doi-reference

Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone

10.1002/ijc.21799 · ExternalCitation · doi-reference

Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line

10.1002/j.1460-2075.1991.tb07676.x · ExternalCitation · doi-reference

MDMX: a novel p53-binding protein with some functional properties of MDM2

10.1002/j.1460-2075.1996.tb00919.x · ExternalCitation · doi-reference

Icaritin inhibits glioblastoma cell viability and glycolysis by blocking the IL‐6/Stat3 pathway

10.1002/jcb.28000 · ExternalCitation · doi-reference

Targeting phosphatidylinositol 3‐kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors

10.1002/med.21770 · ExternalCitation · doi-reference

Targeted Therapy with Anlotinib for a Patient with an Oncogenic

10.1002/onco.13530 · ExternalCitation · doi-reference

Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects

10.1002/ptr.7305 · ExternalCitation · doi-reference

Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer

10.1007/978-3-030-24100-1_2 · ExternalCitation · doi-reference

Neurotrophin signaling: many exciting surprises!

10.1007/s00018-006-6010-1 · ExternalCitation · doi-reference

Functions of the MDM2 oncoprotein

10.1007/s000180050273 · ExternalCitation · doi-reference

Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

10.1007/s00280-012-2043-3 · ExternalCitation · doi-reference

Glioblastomas harboring gene fusions detected by next-generation sequencing

10.1007/s10014-020-00377-9 · ExternalCitation · doi-reference

Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells

10.1007/s10549-010-1304-2 · ExternalCitation · doi-reference

EGFR as a potent CAR T target in triple negative breast cancer brain metastases

10.1007/s10549-022-06783-1 · ExternalCitation · doi-reference

Continuous daily sunitinib for recurrent glioblastoma

10.1007/s11060-012-0988-z · ExternalCitation · doi-reference

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)

10.1007/s11060-019-03194-z · ExternalCitation · doi-reference

Phase II study of Dovitinib in recurrent glioblastoma

10.1007/s11060-019-03236-6 · ExternalCitation · doi-reference

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

10.1007/s11060-019-03337-2 · ExternalCitation · doi-reference

Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation

10.1007/s11060-021-03834-3 · ExternalCitation · doi-reference

Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer

10.1007/s11060-022-04145-x · ExternalCitation · doi-reference

ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449

10.1007/s11060-022-04193-3 · ExternalCitation · doi-reference

Clinical advances in oncolytic virus therapy for malignant glioma: a systematic review

10.1007/s12672-023-00769-1 · ExternalCitation · doi-reference

Targeting IDH-Mutant Glioma

10.1007/s13311-022-01238-3 · ExternalCitation · doi-reference

Vismodegib: A Review in Advanced Basal Cell Carcinoma

10.1007/s40265-018-0948-9 · ExternalCitation · doi-reference

Receptor tyrosine kinase signaling – a proteomic perspective

10.1016/j.advenzreg.2010.10.005 · ExternalCitation · doi-reference

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

10.1016/j.annonc.2020.01.074 · ExternalCitation · doi-reference

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

10.1016/j.annonc.2020.07.014 · ExternalCitation · doi-reference

NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells

10.1016/j.canlet.2015.07.007 · ExternalCitation · doi-reference

Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells

10.1016/j.canlet.2015.11.015 · ExternalCitation · doi-reference

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition

10.1016/j.ccell.2015.08.001 · ExternalCitation · doi-reference

Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas

10.1016/j.ccell.2020.03.011 · ExternalCitation · doi-reference

Cell Signaling by Receptor Tyrosine Kinases

10.1016/j.cell.2010.06.011 · ExternalCitation · doi-reference

The Somatic Genomic Landscape of Glioblastoma

10.1016/j.cell.2013.09.034 · ExternalCitation · doi-reference

Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor

10.1016/j.cell.2018.09.038 · ExternalCitation · doi-reference

Tumor angiogenesis: Current challenges and therapeutic opportunities

10.1016/j.ctarc.2021.100422 · ExternalCitation · doi-reference

Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis

10.1016/j.ejca.2023.112959 · ExternalCitation · doi-reference

Clinical sequencing reveals diagnostic, therapeutic, and prognostic biomarkers for adult-type diffuse gliomas

10.1016/j.heliyon.2024.e37712 · ExternalCitation · doi-reference

The safety and efficacy of tyrosine kinase inhibitors against EGFR in patients with glioma; A systematic review, meta-analysis, and sub-group analysis on glioblastoma

10.1016/j.jocn.2025.111138 · ExternalCitation · doi-reference

ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients

10.1016/j.modpat.2023.100294 · ExternalCitation · doi-reference

The clinical and prognostic role of ALK in glioblastoma

10.1016/j.prp.2021.153447 · ExternalCitation · doi-reference

Glioma epigenetics: From subclassification to novel treatment options

10.1016/j.semcancer.2017.11.010 · ExternalCitation · doi-reference

Blocking Ras inhibition as an antitumor strategy

10.1016/j.semcancer.2018.01.017 · ExternalCitation · doi-reference

RAF-MEK-ERK pathway in cancer evolution and treatment

10.1016/j.semcancer.2021.05.010 · ExternalCitation · doi-reference

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

10.1016/j.semcancer.2021.06.019 · ExternalCitation · doi-reference

EGFR signaling pathway as therapeutic target in human cancers

10.1016/j.semcancer.2022.04.002 · ExternalCitation · doi-reference

Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling

10.1016/j.tcb.2017.06.002 · ExternalCitation · doi-reference

Enabling Technologies for Personalized and Precision Medicine

10.1016/j.tibtech.2019.12.021 · ExternalCitation · doi-reference

Hedgehog Induces Opposite Changes in Turnover and Subcellular Localization of Patched and Smoothened

10.1016/s0092-8674(00)00056-8 · ExternalCitation · doi-reference

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

10.1016/s0140-6736(12)60868-x · ExternalCitation · doi-reference

The Raf/MEK/ERK pathway: new concepts of activation

10.1016/s0248-4900(01)01125-x · ExternalCitation · doi-reference

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα

10.1016/s0960-9822(06)00122-9 · ExternalCitation · doi-reference

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

10.1016/s1470-2045(18)30119-0 · ExternalCitation · doi-reference

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

10.1021/acs.jmedchem.7b00930 · ExternalCitation · doi-reference

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

10.1021/acsmedchemlett.9b00509 · ExternalCitation · doi-reference

To cycle or not to cycle: a critical decision in cancer

10.1038/35106065 · ExternalCitation · doi-reference

Differential regulation of rasGAP and neurofibromatosis gene product activities

10.1038/351576a0 · ExternalCitation · doi-reference

A mammalian protein targeted by G1-arresting rapamycin–receptor complex

10.1038/369756a0 · ExternalCitation · doi-reference

PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3

10.1038/ncomms15223 · ExternalCitation · doi-reference

The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma

10.1038/ng.2938 · ExternalCitation · doi-reference

Neurofibromin regulates G protein–stimulated adenylyl cyclase activity

10.1038/nn792 · ExternalCitation · doi-reference

A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor

10.1038/nrc3911 · ExternalCitation · doi-reference

Targeting the Hedgehog pathway in cancer

10.1038/nrd2086 · ExternalCitation · doi-reference

NVP-LDE-225 (Erismodegib) inhibits epithelial–mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128

10.1038/oncsis.2013.5 · ExternalCitation · doi-reference

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies

10.1038/s41388-017-0045-7 · ExternalCitation · doi-reference

Signaling pathways in brain tumors and therapeutic interventions

10.1038/s41392-022-01260-z · ExternalCitation · doi-reference

Glioblastoma at the crossroads: current understanding and future therapeutic horizons

10.1038/s41392-025-02299-4 · ExternalCitation · doi-reference

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

10.1038/s41416-020-01157-0 · ExternalCitation · doi-reference

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

10.1038/s41416-020-0814-x · ExternalCitation · doi-reference

Medulloblastoma

10.1038/s41572-019-0063-6 · ExternalCitation · doi-reference

PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis

10.1038/s41586-020-1952-2 · ExternalCitation · doi-reference

A vaccine targeting mutant IDH1 in newly diagnosed glioma

10.1038/s41586-021-03363-z · ExternalCitation · doi-reference

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

10.1038/s41591-022-02141-2 · ExternalCitation · doi-reference

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

10.1038/s41591-023-02668-y · ExternalCitation · doi-reference

ALK fusions in the pan-cancer setting: another tumor-agnostic target?

10.1038/s41698-023-00449-x · ExternalCitation · doi-reference

The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways

10.1038/sj.cdd.4402057 · ExternalCitation · doi-reference

Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh

10.1038/srep18830 · ExternalCitation · doi-reference

BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma

10.1038/srep20189 · ExternalCitation · doi-reference

Histone mutations in cancer

10.1042/bst20210567 · ExternalCitation · doi-reference

DBS Assay with LC-MS/MS for the Determination of Idelalisib, A Selective PI3K-δ Inhibitor in Mice Blood and Its Application to a Pharmacokinetic Study

10.1055/a-1252-2476 · ExternalCitation · doi-reference

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

10.1056/nejmoa1103782 · ExternalCitation · doi-reference

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

10.1056/nejmoa1308345 · ExternalCitation · doi-reference

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

10.1056/nejmoa1308573 · ExternalCitation · doi-reference

Alpelisib for

10.1056/nejmoa1813904 · ExternalCitation · doi-reference

Selumetinib in Children with Inoperable Plexiform Neurofibromas

10.1056/nejmoa1912735 · ExternalCitation · doi-reference

Repotrectinib in

10.1056/nejmoa2302299 · ExternalCitation · doi-reference

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

10.1056/nejmoa2304194 · ExternalCitation · doi-reference

The NF1 tumor suppressor critically regulates TSC2 and mTOR

10.1073/pnas.0503224102 · ExternalCitation · doi-reference

Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres

10.1073/pnas.1008850107 · ExternalCitation · doi-reference

Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α

10.1073/pnas.1009652107 · ExternalCitation · doi-reference

Expression and rearrangement of the ROS1 gene in human glioblastoma cells

10.1073/pnas.84.24.9270 · ExternalCitation · doi-reference

Stabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein

10.1074/jbc.274.53.38189 · ExternalCitation · doi-reference

Pleiotrophin Signaling through Anaplastic Lymphoma Kinase Is Rate-limiting for Glioblastoma Growth

10.1074/jbc.m112354200 · ExternalCitation · doi-reference

The Neurofibromatosis Type 1 Gene Product Neurofibromin Enhances Cell Motility by Regulating Actin Filament Dynamics via the Rho-ROCK-LIMK2-Cofilin Pathway

10.1074/jbc.m503707200 · ExternalCitation · doi-reference

PTEN, Stem Cells, and Cancer Stem Cells

10.1074/jbc.r800071200 · ExternalCitation · doi-reference

A History of von Recklinghausen's NF1

10.1080/09647041003642885 · ExternalCitation · doi-reference

Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions

10.1080/17512433.2021.1947246 · ExternalCitation · doi-reference

Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series

10.1093/annonc/mdi317 · ExternalCitation · doi-reference

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

10.1093/annonc/mdw282 · ExternalCitation · doi-reference

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

10.1093/annonc/mdy263 · ExternalCitation · doi-reference

GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors

10.1093/jnen/nlz093 · ExternalCitation · doi-reference

A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study

10.1093/neuonc/noaa071 · ExternalCitation · doi-reference

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

10.1093/neuonc/noab106 · ExternalCitation · doi-reference

Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making

10.1093/neuonc/noab282 · ExternalCitation · doi-reference

Entrectinib in children and young adults with solid or primary CNS tumors harboring

10.1093/neuonc/noac087 · ExternalCitation · doi-reference

Olutasidenib (FT-2102) in patients with relapsed or refractory

10.1093/neuonc/noac139 · ExternalCitation · doi-reference

EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection

10.1093/neuonc/noad008 · ExternalCitation · doi-reference

A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered

10.1093/neuonc/noad144 · ExternalCitation · doi-reference

Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection—Update 1

10.1093/neuonc/noae213 · ExternalCitation · doi-reference

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

10.1093/neuonc/noq198 · ExternalCitation · doi-reference

Toward precision medicine in glioblastoma: the promise and the challenges

10.1093/neuonc/nov031 · ExternalCitation · doi-reference

Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma

10.1093/neuonc/nov083 · ExternalCitation · doi-reference

FGFR-TACC gene fusions in human glioma

10.1093/neuonc/now240 · ExternalCitation · doi-reference

Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence

10.1093/neuonc/nox018 · ExternalCitation · doi-reference

Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma

10.1093/neuonc/nox109 · ExternalCitation · doi-reference

Prognostic relevance of genetic alterations in diffuse lower-grade gliomas

10.1093/neuonc/nox132 · ExternalCitation · doi-reference

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy

10.1093/neuonc/nox151 · ExternalCitation · doi-reference

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy

10.1093/neuonc/nox154 · ExternalCitation · doi-reference

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis

10.1093/noajnl/vdaa082 · ExternalCitation · doi-reference

Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma

10.1093/noajnl/vdab097 · ExternalCitation · doi-reference

Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?

10.1093/noajnl/vdab133 · ExternalCitation · doi-reference

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study

10.1093/noajnl/vdab188 · ExternalCitation · doi-reference

NF1 Gene and Neurofibromatosis 1

10.1093/oxfordjournals.aje.a010118 · ExternalCitation · doi-reference

Co-localization of Patched and activated Sonic hedgehog to lysosomes in neurons

10.1097/00001756-200002280-00030 · ExternalCitation · doi-reference

Transcriptional activation of hedgehog target genes in Drosophila is mediated directly by the cubitus interruptus protein, a member of the GLI family of zinc finger DNA-binding proteins.

10.1101/gad.10.16.2003 · ExternalCitation · doi-reference

CDK inhibitors: positive and negative regulators of G1-phase progression

10.1101/gad.13.12.1501 · ExternalCitation · doi-reference

The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3

10.1101/gad.566910 · ExternalCitation · doi-reference

Icaritin inhibits the invasion and epithelial‐to‐mesenchymal transition of glioblastoma cells by targeting EMMPRIN via PTEN/AKt/HIF‐1

10.1111/1440-1681.12488 · ExternalCitation · doi-reference

Radiotherapy plus temozolomide with or without anlotinib in H3K27M‐mutant diffuse midline glioma: A retrospective cohort study

10.1111/cns.14730 · ExternalCitation · doi-reference

Decreased expression of neurofibromin contributes to epithelial–mesenchymal transition in neurofibromatosis type 1

10.1111/j.1600-0625.2009.01017.x · ExternalCitation · doi-reference

Genetic Alterations and Aberrant Expression of Genes Related to the Phosphatidyl‐lnositol‐3′‐Kinase/Protein Kinase B (Akt) Signal Transduction Pathway in Glioblastomas

10.1111/j.1750-3639.2003.tb00481.x · ExternalCitation · doi-reference

Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

10.1126/science.1106148 · ExternalCitation · doi-reference

10.1126/science.1179386

10.1126/science.1179386 · ExternalCitation · doi-reference

The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling

10.1126/science.1199498 · ExternalCitation · doi-reference

A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival

10.1126/science.1234907 · ExternalCitation · doi-reference

The Phosphoinositide 3-Kinase Pathway

10.1126/science.296.5573.1655 · ExternalCitation · doi-reference

The Tumor Suppressor PTEN Is Exported in Exosomes and Has Phosphatase Activity in Recipient Cells

10.1126/scisignal.2003084 · ExternalCitation · doi-reference

Anaplastic lymphoma kinase expression and gene alterations in glioblastoma: correlations with clinical outcome

10.1136/jclinpath-2016-204102 · ExternalCitation · doi-reference

Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer

10.1146/annurev.cellbio.17.1.615 · ExternalCitation · doi-reference

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

10.1158/0008-5472.can-07-6854 · ExternalCitation · doi-reference

Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

10.1158/1078-0432.ccr-06-0773 · ExternalCitation · doi-reference

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

10.1158/1078-0432.ccr-08-0260 · ExternalCitation · doi-reference

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE

10.1158/1078-0432.ccr-17-0764 · ExternalCitation · doi-reference

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma

10.1158/1078-0432.ccr-18-1052 · ExternalCitation · doi-reference

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

10.1158/1078-0432.ccr-19-2808 · ExternalCitation · doi-reference

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in

10.1158/1078-0432.ccr-21-0032 · ExternalCitation · doi-reference

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

10.1158/1078-0432.ccr-21-0611 · ExternalCitation · doi-reference

Infigratinib in Patients with Recurrent Gliomas and

10.1158/1078-0432.ccr-21-2664 · ExternalCitation · doi-reference

10.1158/1078-0432.ccr-21-3521

10.1158/1078-0432.ccr-21-3521 · ExternalCitation · doi-reference

TRKing Down an Old Oncogene in a New Era of Targeted Therapy

10.1158/2159-8290.cd-14-0765 · ExternalCitation · doi-reference

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

10.1158/2159-8290.cd-16-1080 · ExternalCitation · doi-reference

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

10.1158/2159-8290.cd-16-1237 · ExternalCitation · doi-reference

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors

10.1158/2159-8290.cd-18-1175 · ExternalCitation · doi-reference

Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma

10.1159/000502483 · ExternalCitation · doi-reference

Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis

10.1172/jci62727 · ExternalCitation · doi-reference

10.1177/11795549211068804

10.1177/11795549211068804 · ExternalCitation · doi-reference

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial

10.1186/1471-2407-13-299 · ExternalCitation · doi-reference

Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis

10.1186/1479-7364-5-6-623 · ExternalCitation · doi-reference

Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial

10.1186/s12885-023-11776-4 · ExternalCitation · doi-reference

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

10.1186/s12885-024-11820-x · ExternalCitation · doi-reference

p53 signaling in cancer progression and therapy

10.1186/s12935-021-02396-8 · ExternalCitation · doi-reference

Mechanisms of receptor tyrosine kinase activation in cancer

10.1186/s12943-018-0782-4 · ExternalCitation · doi-reference

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

10.1186/s12943-018-0796-y · ExternalCitation · doi-reference

Targeting PI3K in cancer: mechanisms and advances in clinical trials

10.1186/s12943-019-0954-x · ExternalCitation · doi-reference

Glioma targeted therapy: insight into future of molecular approaches

10.1186/s12943-022-01513-z · ExternalCitation · doi-reference

Cancer combination therapies by angiogenesis inhibitors; a comprehensive review

10.1186/s12964-022-00838-y · ExternalCitation · doi-reference

MET in glioma: signaling pathways and targeted therapies

10.1186/s13046-019-1269-x · ExternalCitation · doi-reference

Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation

10.1186/s13148-019-0759-1 · ExternalCitation · doi-reference

Ivosidenib in Isocitrate Dehydrogenase 1

10.1200/jco.19.03327 · ExternalCitation · doi-reference

NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas

10.1200/jco.20.02220 · ExternalCitation · doi-reference

Correlation of O

10.1200/jco.2007.11.5964 · ExternalCitation · doi-reference

Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

10.1200/jco.2008.16.9235 · ExternalCitation · doi-reference

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

10.1200/jco.2009.26.3988 · ExternalCitation · doi-reference

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O

10.1200/jco.2015.64.7685 · ExternalCitation · doi-reference

Medulloblastoma: From Myth to Molecular

10.1200/jco.2017.72.7842 · ExternalCitation · doi-reference

BRAF Inhibition in

10.1200/jco.2018.78.9990 · ExternalCitation · doi-reference

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

10.1200/jco.22.02772 · ExternalCitation · doi-reference

ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma

10.1200/jco.23.01134 · ExternalCitation · doi-reference

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma

10.1200/jco.24.01034 · ExternalCitation · doi-reference

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in

10.1200/po.17.00063 · ExternalCitation · doi-reference

Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma

10.1200/po.18.00071 · ExternalCitation · doi-reference

Analysis of

10.1200/po.18.00183 · ExternalCitation · doi-reference

Activity of Pemigatinib in Pilocytic Astrocytoma and

10.1200/po.21.00371 · ExternalCitation · doi-reference

Biochemical mechanisms of vertebrate hedgehog signaling

10.1242/dev.166892 · ExternalCitation · doi-reference

NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells

10.1371/journal.pone.0047249 · ExternalCitation · doi-reference

Comprehensive Molecular Genetic Analysis in Glioma Patients by Next Generation Sequencing

10.14791/btrt.2023.0036 · ExternalCitation · doi-reference

Tangeretin: a mechanistic review of its pharmacological and therapeutic effects

10.1515/jbcpp-2019-0191 · ExternalCitation · doi-reference

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways

10.1586/14737140.3.5.595 · ExternalCitation · doi-reference

Enhanced Antitumorigenic Effects in Glioblastoma on Double Targeting of Pleiotrophin and Its Receptor ALK

10.1593/neo.81040 · ExternalCitation · doi-reference

DNA alkylation lesion repair: outcomes and implications in cancer chemotherapy

10.1631/jzus.b2000344 · ExternalCitation · doi-reference

Cyclopamine-Mediated Hedgehog Pathway Inhibition Depletes Stem-Like Cancer Cells in Glioblastoma

10.1634/stemcells.2007-0166 · ExternalCitation · doi-reference

Neoplasms Associated with Germline and Somatic

10.1634/theoncologist.2010-0181 · ExternalCitation · doi-reference

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

10.1634/theoncologist.2017-0691 · ExternalCitation · doi-reference

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma

10.1634/theoncologist.2018-0149 · ExternalCitation · doi-reference

Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients

10.1681/asn.2007111202 · ExternalCitation · doi-reference

The

10.18632/oncotarget.2194 · ExternalCitation · doi-reference

EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma

10.18632/oncotarget.27389 · ExternalCitation · doi-reference

Efficacy of osimertinib against EGFRvIII+ glioblastoma

10.18632/oncotarget.27599 · ExternalCitation · doi-reference

Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells

10.18632/oncotarget.346 · ExternalCitation · doi-reference

Isoform-Selective PI3K Inhibitors for Various Diseases

10.2174/1568026620666200106141717 · ExternalCitation · doi-reference

Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights

10.2174/1570159x15666171129111324 · ExternalCitation · doi-reference

Clinical activity of the

10.2217/cns-2019-0014 · ExternalCitation · doi-reference

Copanlisib in the treatment of non-Hodgkin lymphoma

10.2217/fon-2020-0195 · ExternalCitation · doi-reference

Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis

10.26355/eurrev_202111_27092 · ExternalCitation · doi-reference

Clinical Experience using Osimertinib in Patients with Recurrent Malignant Gliomas Containing EGFR Alterations

10.26502/jcsct.5079114 · ExternalCitation · doi-reference

PDGF and PDGF receptors in glioma

10.3109/03009734.2012.665097 · ExternalCitation · doi-reference

Aberrant G protein signaling in nervous system tumors

10.3171/jns.2002.97.3.0627 · ExternalCitation · doi-reference

CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future

10.3389/fimmu.2022.817296 · ExternalCitation · doi-reference

O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy

10.3389/fonc.2019.01547 · ExternalCitation · doi-reference

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution

10.3389/fonc.2022.1067252 · ExternalCitation · doi-reference

Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future

10.3389/fonc.2022.911876 · ExternalCitation · doi-reference

AKT Inhibitor SC66 Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Through Down-Regulating AKT/β-Catenin Pathway

10.3389/fphar.2020.01102 · ExternalCitation · doi-reference

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis

10.3389/fphar.2021.804942 · ExternalCitation · doi-reference

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors

10.3390/cancers11091262 · ExternalCitation · doi-reference

An Update on Neurofibromatosis Type 1-Associated Gliomas

10.3390/cancers12010114 · ExternalCitation · doi-reference

Anaplastic Lymphoma Kinase (ALK) in Posterior Cranial Fossa Tumors: A Scoping Review of Diagnostic, Prognostic, and Therapeutic Perspectives

10.3390/cancers16030650 · ExternalCitation · doi-reference

Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors

10.3390/cancers8020022 · ExternalCitation · doi-reference

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

10.3390/cells9010198 · ExternalCitation · doi-reference

The Importance of Being PI3K in the RAS Signaling Network

10.3390/genes12071094 · ExternalCitation · doi-reference

The Role of Smoothened in Cancer

10.3390/ijms21186863 · ExternalCitation · doi-reference

HGF/MET Signaling in Malignant Brain Tumors

10.3390/ijms21207546 · ExternalCitation · doi-reference

Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis

10.3390/ijms22115850 · ExternalCitation · doi-reference

MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies

10.3390/ijms232213898 · ExternalCitation · doi-reference

The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy

10.3390/ijms232415585 · ExternalCitation · doi-reference

Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities

10.3390/ijms24032651 · ExternalCitation · doi-reference

Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities

10.3390/ijms25042316 · ExternalCitation · doi-reference

Contributions of Noncanonical Smoothened Signaling During Embryonic Development

10.3390/jdb5040011 · ExternalCitation · doi-reference

Current Development Status of MEK Inhibitors

10.3390/molecules22101551 · ExternalCitation · doi-reference

Consequences of

10.3390/molecules24050968 · ExternalCitation · doi-reference

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors

10.3390/molecules27030819 · ExternalCitation · doi-reference

NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5

10.3892/ijo.2015.3035 · ExternalCitation · doi-reference

Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials

10.3892/mco.2016.816 · ExternalCitation · doi-reference

Activation of sonic hedgehog signaling enhances cell migration and invasion by induction of matrix metalloproteinase-2 and -9 via the phosphoinositide-3 kinase/AKT signaling pathway in glioblastoma

10.3892/mmr.2015.4229 · ExternalCitation · doi-reference

Hedgehog signaling regulates the development and treatment of glioblastoma (Review)

10.3892/ol.2022.13414 · ExternalCitation · doi-reference

PI3Kβ inhibitor AZD6482 exerts antiproliferative activity and induces apoptosis in human glioblastoma cells

10.3892/or.2018.6845 · ExternalCitation · doi-reference

Bevacizumab: Review of Development, Pharmacology, and Application to Brain Tumors

10.4137/cmt.s2042 · ExternalCitation · doi-reference

State of the Art of Smo Antagonists for Cancer Therapy: Advances in the Target Receptor and New Ligand Structures

10.4155/fmc-2018-0497 · ExternalCitation · doi-reference

Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial

10.7150/jca.30123 · ExternalCitation · doi-reference